Cost effectiveness analysis of blinatumomab in pediatric patients with relapsed or refractory precursor B-Cell acute lymphoblastic leukemia in China
Objective To compare the cost effectiveness of blinatumomab and chemotherapy in the treatment of relapsed or refractory precursor B-Cell acute lymphoblastic leukemia(ALL)from Chinese societal perspective.Methods A partition survival model with three health states(event-free,recurrence and death)was conducted over a 20 years horizon.Clinical data accessed from the phase Ⅲ randomized controlled clinical study 20120215,utility values were obtained from the quality of life study of leukemia patients in Shanghai Children's Medical Centre,and cost inputs were identified from the Eliancloud database,Menet database,National Bureau of Statistics etc.The threshold of willingness to pay(WTP)was CNY 128 547(1.50 times of 2022 Chinese per capita GDP).Deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted to access the robustness of model and findings.Results The patients of intervention group achieved 8.74 quality-adjusted life years(QALYs)and 10.53 life years(LYs),compared with control group,an increase of 3.01 QALYs and 3.46 LYs.The total cost for intervention group was CNY 1 060 929,an increase of CNY 245 719 compared with control group.The incremental cost effectiveness ratio(ICER)in intervention group compared with control group was CNY 81 623 per QALY.Results were robust to sensitivity analyses.Conclusion Blinatumomab is more cost effective in pediatric patients with relapsed or refractory precursor B-Cell ALL compared with chemotherapy from Chinese societal perspective.
NETL
NSTL
万方数据
